When the world raved about the aftermath of the coronavirus, with over 2,677,527 and 187,537 deaths confirmed in over 200 countries around the world, Oxford University scientists rises hope of a solution.
Oxford University has started its COVID-19 vaccine trials on the first human. In the test, two volunteers were injected with the vaccine sample in a controlled amount.
While over 800 people were recruited for the study, only half are injected with the COVID-19 vaccine and the other half with the meningitis vaccine. With the approach, the volunteers will not know which vaccines were injected, but only the doctors will know.
Elisa Granato, one of the two who received the stab, said that she is also a scientist and ready to support the scientific process wherever possible. Oxford University’s scientific team made the vaccine in three months.
During development, preclinical research was led by Sara Gilbert, professor of vaccinology at the Jenner Institute. The professor said that she had a high level of confidence in the vaccine being developed.
She made it clear that it is important for human trials so that data can be proved. In this way, it can be shown whether the vaccine protects people from infection with COVID-19 before it is used in a wider population.
Previously, the professor had agreed that he is 80% certain that the vaccine will work, but on Thursday he did not prefer to re-enter a number, just to say that she is optimistic that it will work.
The COVID-19 vaccine, developed by scientists at Oxford University and currently being tested in human trials, was made from a weakened version of a cold virus identified as a chimpanzee adenovirus.
It is a great hope that what they have developed will be successful. The same team at the university developed the vaccine against Mers, another type of coronavirus, using the same approach that promised clinical trial results.
However, the team can only determine whether the vaccine is effective against COVID-19 by comparing the number of new cases reported after using the vaccine. However, this can be a problem because there are already damage mitigation measures, such as closures, that are promising.
Pro Andre Pollard, director of the Oxford Vaccine Group and head of the study, said the team is following the end of the current epidemic wave. If the team doesn’t catch that, they can’t tell if the vaccine is working.
It has been a priority for local health workers to be involved in the studies as they are the ones at risk of infection while caring for the infected.
In the coming months, more than 5,000 volunteers are expected to be injected with the vaccine.
Although the team does not specify the age factor, it is evident that older people tend to have a weaker immune response to vaccines.
The team had previously considered testing its vaccine in Africa, possibly in Kenya, where there is a less sophisticated health system and where the cases are high.
Nelson Richards is a Seasoned Journalist with nearly 6 years of experience. While studying at Case Western Reserve University, Located at Cleveland. Nelson found a passion for finding and writing articles which are published in Well known Media Publications such as Tnt Publications and Ohio News Network. As a contributor to Chroniclex Nelson Covers National Topics.